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Objectives: The late effects of RT are not well reported in patients with oral tongue 
cancer (OTC). This study reports the incidence of late effects and factors associated with 
the development of late effects in OTC patients.
Methods: Patients with OTC treated in our institution from 2003 to 2013 were evalu-
ated. The association between RT doses, including mandible maximum and minimum 
doses and total 3D maximum dose, and late toxicity, defined as development of osteora-
dionecrosis (ORN), percutaneous endoscopic gastrostomy (PEG) tube dependence for 
>6 months after treatment, and narcotic dependency >6 months posttreatment were 
assessed using both univariate and multivariable (MV) analysis.
results: Seventy-six patients with OTC (45% males and 55% females) were treated 
with definitive surgical resection followed by adjuvant RT. The median follow-up was 
4.3 years. Combined late toxicities were reported in 38% of patients. Thirty-four per-
cent of the patients had narcotic dependency and, 3.9% of the patients had ORN of 
the mandible. Thirteen percent of patients developed PEG tube dependency that was 
significantly associated with a higher 3D maximum radiation dose on univariate analysis 
(p < 0.01). On MV analysis, 3D maximum dose remained significantly associated with 
long-term PEG tube dependency (p = 0.05).
conclusion: Patients with OTC treated with adjuvant RT are at significant risk for devel-
opment of late toxicities. Increasing maximum dose is associated with long-term PEG 
tube dependence, and care should be taken to reduce the “hot spot” within radiation 
treatment plans as much as possible.
Keywords: oral tongue cancer, radiation therapy, Peg tube dependency, osteoradionecrosis, narcotic dependency
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inTrODUcTiOn
Cancers of the oral tongue represent the most common pri-
mary site of oral cavity cancer (OCC), the majority of which 
are squamous cell carcinomas. In 2014, approximately 28,030 
patients were diagnosed with OCC, of which 13,590 had oral 
tongue cancer (OTC) (1). The current standard of care for OTC 
is surgical resection followed by adjuvant therapy depending 
on pathological characteristics of disease (2, 3). Notably, the 
survival benefit of elective neck dissection at the time of initial 
surgical management relative to salvage neck dissection at the 
time of nodal relapse was recently reported in a randomized 
control trial (4). After resection, the presence of adverse 
pathological features, specifically bone invasion, tumor thick-
ness >4 mm, lymphovascular or perineural invasion (PNI), or 
multiple positive lymph nodes are indications for postoperative 
management with RT (5,  6). Surgical resection followed by 
concurrent chemotherapy and RT is recommended for patients 
with positive margins or lymph nodes with extracapsular 
extension (3, 7, 8).
Advances in reconstructive surgery have led to better func-
tional outcomes following primary surgical resection (9). RT 
and concurrent, radiosensitizing chemotherapy continue to be 
integral components of the treatment paradigm to improve both 
locoregional control and survival; Radiation Therapy Oncology 
Group (RTOG) (8) and EORTC (7) trials showed 10% improve-
ment in locoregional control in head and neck cancer patients 
treated with concurrent postoperative chemotherapy and radio-
therapy relative to radiation therapy alone. These improvements 
in locoregional control, however, come at the expense of increased 
toxicities. In RTOG 9501 and EORTC 22931 trials, the incidence 
of grade ≥3 acute toxicity is approximately twice as high with 
concurrent treatment; however, grade 3 or higher late toxicities 
were similar among the groups in RTOG and EORTC trials, at 
approximately 30–40%.
Given such high rates of grade 3 or higher late toxicities in 
postoperative head and neck cancer patients, the goal of this study 
was to retrospectively analyze clinical and treatment-related vari-
ables that may contribute to the development of late side effects 
within OTC patients. Specific late toxicity endpoints in this study 
include osteoradionecrosis (ORN) of the mandible, long-term 
percutaneous endoscopic gastrostomy (PEG) tube dependence, 
and long-term narcotic dependency.
MaTerials anD MeThODs
study Population
After Institutional Review Board (IRB) approval at the Winship 
Cancer Institute of Emory University, a retrospective chart 
review of OTC patients treated between 2003 and 2013 was 
performed (IRB code number: 00016211). Inclusion criteria 
for this study included a confirmed diagnosis of squamous cell 
carcinoma of the oral tongue and surgical resection followed by 
RT delivered at Winship Cancer Institute. Patients treated by 
surgical resection alone, patients receiving adjuvant treatment 
outside of Emory, and patients with any distant metastases 
at the time of diagnosis were excluded from this study. All 
patients had routine pretreatment evaluations consisting of a 
complete history, physical examination, blood tests, computed 
tomography (CT), or positron emission tomography (PET) of 
the head and neck region and chest X-ray or chest CT as clini-
cally appropriate.
Data collection
All data were collected using electronic medical records and 
departmental radiation oncology charts. The clinical parameters 
of interest included tumor characteristics, stage, age, radiation 
techniques and dose, treatment dates, and late toxicities fol-
lowing radiation. In this study, data for late toxicity including 
ORN, PEG tube placement, and narcotic dependency rates 
were retrieved from clinical notes at each follow-up visit. All 
radiological examination reports were reviewed for general 
pathological changes and for changes specific to ORN lesions. 
PEG tube dependency was reported as continuation of tube 
feedings 6  months after completion of treatment and narcotic 
dependency as continued use after 6 months of completion of 
treatment.
radiotherapy Planning and Delivery
Computed tomography simulation was completed following 
the surgery using a GE Lightspeed Large Bore CT Scanner (GE 
Healthcare, Waukesha, WI, USA). A thermoplastic head and 
shoulder mask (WFR/Aquaplast Corporation, Wyckoff, NJ, USA) 
was used for each patient during simulation and treatment for 
immobilization. The treatment planning CT and intravenous 
contrast was matched with PET (if obtained) in the treatment 
position to better define target volumes. The RTOG guidelines 
were used to contour organs at risk (OARs) (10). Dose calcula-
tions were performed in Eclipse Treatment Planning System 
v10.6 (Varian Medical Systems, Palo Alto, CA, USA) using 
the convolution/superposition algorithm to correct for tissue 
heterogeneities. Treatments were delivered by using a Varian 
Linear Accelerator (Varian Medical Systems, Palo Alto, CA, USA) 
with 6 MV photons with intensity-modulated radiation therapy 
(IMRT) or volumetric-modulated arc therapy techniques. Daily 
onboard imaging with KV X-rays was obtained prior to each 
treatment, with MV imaging utilized only if KV imaging was 
unavailable. Dosimetric variables were captured from eclipse 
planning software and recorded, including 3D maximum dose, 
prescribed total dose, and mandible minimum, maximum, and 
mean doses.
statistical analysis
Statistical analysis was performed using SAS 9.4 statistical soft-
ware (SAS Institute Inc., Cary, NC, USA). Categorical variables 
were compared across toxicity endpoints using chi-squared 
tests or Fisher’s exact tests, where appropriate, while continuous 
variables were compared across endpoints using ANOVA. For 
the multivariable (MV) logistic regression models, we modeled 
the probability of an event (long-term narcotic dependence, PEG 
tube dependence, or any adverse event) as a function of 3D maxi-
mum dose (%) and the three most significant predictors in each 
TaBle 2 | Treatment characteristics.
no. of patients (%)
Radiology
CT 57 (75)
PET/CT 19 (25)
Chemotherapy
None 51 (67)
Cisplatin 18 (24)
Carboplatin and paclitaxel 6 (8)
Cetuximab 1 (1)
Concurrent chemoradiotherapy 25 (33)
Surgical procedure
Primary alone 7 (9)
Primary and ND 69 (91)
Radiation therapy
Prescribed dose
Median 63 Gy
Range (59.4–70.29 Gy)
Fraction size
Median 2 Gy
Range (1.8–2.2 Gy)
3D dose max (%)
Mean 109
Median 109
Range (104–129)
Mandible min. dose
Mean 3.5 Gy
Median 2 Gy
Range (0–13 Gy)
Mandible max. dose
Mean 63 Gy
Median 66 Gy
Range (10–85 Gy)
Mandible median dose
Mean 47 Gy
Median 50 Gy
Range (8–76 Gy)
ND, neck dissection; CT, computed tomography; PET, positron emission tomography.
TaBle 1 | Patient characteristics.
characteristics no. of patients (%)
Age (y)
Median 56
Range 15–89
Race
White 59 (78)
Other 17 (22)
Gender
Female 42 (55)
Male 34 (45)
Histology
SCC 76 (100)
T stage
T1 35 (46)
T2 21 (28)
T3 8 (10)
T4 12 (16)
N stage
N0 42 (55)
N1 19 (25)
N2 15 (20)
Bone invasion 3 (4)
PNI 42 (55)
ALI 23 (30)
SCC, squamous cell carcinoma; PNI, perineural invasion; ALI, angiolymphatic invasion; 
y, year.
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univariate comparison. For ORN, we modeled the probability of 
ORN as a function of mandible minimum dose (%) and mandible 
maximum dose (%). The number of variables in each MV model 
was restricted due to the low number of toxicity events.
resUlTs
Patient and Treatment characteristics
Seventy six patients (45% males and 55% females) met the inclu-
sion criteria. The median follow-up time was 4.3 years. Patient 
characteristics are demonstrated in Table 1. Median age at diag-
nosis was 56 years (range, 15–89 years). Squamous cell carcinoma 
was the histology type among all patients. PNI was present in 55% 
of the patients and angiolymphatic invasion in 30%. Three (4%) 
patients had a bone invasion. Margins were positive in 7% of the 
patients and <5 mm in 30%. Moderately differentiated tumor was 
the most prevalent, reported in 58% of the patients.
Table 2 summarizes the treatment characteristics. Thirty-three 
percent of the patients received chemotherapy. Cisplatin and 
carboplatin/paclitaxel were the most frequently used regimens. 
Chemotherapy was administered concurrently with RT in all 
patients receiving chemotherapy. The primary tumor alone was 
resected without neck dissection in 9% of patients. Partial glos-
sectomy plus unilateral neck dissection was performed in 91% 
of patients. Total glossectomy was performed on three patients. 
Radiation dose was between 59.4 and 70.29 Gy in 1.8–2.2 Gy per 
fraction in all patients (Table 2). The median 3D dose maximum 
was found to be 109% (range, 104–129%).
late Toxicity
Late toxicity was reported in 38% of patients. Three patients 
developed ORN alone or with other late toxicities, 10 patients 
had PEG tube dependency alone or with other late toxicities, 
and 26 patients had narcotic dependency alone or with other 
late toxicities (Table 3). Receipt of chemotherapy had no influ-
ence on the development of late toxicities (p = 0.439). Surgical 
procedures alone had no significant effect on reported late 
toxicities (p =  0.468). Median prescribed radiation dose was 
63 Gy (range, 59.4–70.29) in patients with no toxicity and iden-
tical in patients who developed the late toxicities. Furthermore, 
there was no significant difference in fraction size (p = 0.643). 
There were no significant differences in mandibular median 
(p = 0.847), maximum (p = 0.334), or minimum (p = 0.834) 
doses in patients who developed late toxicities versus those who 
did not.
Individual late toxicities—ORN, PEG tube dependency, 
and narcotic dependency—were then analyzed separately 
(Table 4). The 3D maximum dose (%) was statistically significant 
TaBle 5 | Multivariable analysis for late toxicities.
Odds ratio (95% ci) p
long-term Peg dependence
3D dose max 1.27 (1.00–1.61) 0.05
T stage (reference = T4)
T1 0.46 (0.03–6.29) 0.08
T2 1.12 (0.12–9.97)
T3 0.62 (0.03–13.45)
Margins (reference ≤5 mm) 0.26
Positive 1.21 (0.09–16.84)
Negative 0.26 (0.05–1.43)
Radiology (reference = CT)
PET/CT 1.88 (0.32–10.96) 0.48
Osteoradionecrosis
Mandible min. dose (%) 0.87 (0.57–1.32) 0.51
Mandible max. dose (%) 0.97 (0.93–1.01) 0.18
long-term narcotic dependence
3D dose max (%) 0.97 (0.83–1.12) 0.65
PNI (reference = negative) 0.97 (0.83–1.12) 0.21
ALI (reference = negative) 0.61 (0.18–2.11) 0.44
Treatment group (reference = post-CRT) 0.66
Surgery 1.46 (0.33–6.55)
Postoperative RT 0.83 (0.21–3.20)
CI, confidence interval; min, minimum; max, maximum; PET, positron emission 
tomography; CT, computed tomography; PNI, perineural invasion; ALI, angiolymphatic 
invasion; RT, radiation therapy; CRT, chemoradiation therapy.
TaBle 4 | Univariate analysis of dosimetric parameters.
Parameters Yes no p
Peg tube dependence
3D dose max (%) 0.002
Mean 112.5 108.8
Median 110.7 108.7
Number of patients 10 66
narcotic dependence
3D dose max (%) 0.53
Mean 108.9 109.5
Median 108.3 109.4
Number of patients 26 50
Osteoradionecrosis
3D dose max (%) 0.12
Mean 106.0 109.4
Median 106.9 109.2
Number of patients 3 73
max, maximum; PEG, percutaneous endoscopic gastrostomy.
TaBle 3 | late toxicity outcomes.
no. of patients with  
late toxicity
% of patients with 
late toxicity
ORN 3 3.9
PEG dependence at 6 mo 10 13
Narcotic dependency 26 34
Total patients with late toxicity 29 38
ORN, osteoradionecrosis; PEG, percutaneous endoscopic gastrostomy; mo, month.
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for long-term PEG tube dependency on univariate analysis 
(p =  0.002). On MV analysis, the 3D maximum dose (%) was 
significantly associated with long-term PEG tube dependency 
(Table 5).
DiscUssiOn
In the present study, we demonstrate that 38% of patients with 
OTC developed late toxicities (inclusive of long-term PEG 
dependence, ORN, and long-term narcotic dependence) after 
surgical resection and adjuvant radiation treatment. When 
analyzing all late toxicities together, there were no specific vari-
ables associated with the development of late toxicities. However, 
when analyzing individual late toxicities, the maximum radiation 
dose, or “hot spot,” was significantly higher in patients with long-
term PEG tube dependency on both univariate and multivariate 
analysis.
Mitigation of toxicities and mechanisms to improve quality-
of-life are areas of active research for patients with OTC. While 
the addition of chemotherapy to postoperative radiation 
improved 5-year overall survival rate from 40 to 53% in EORTC 
trial, it also resulted in increased toxicity (7). Aside from acute 
toxicity, treatment-associated adverse effects remain prominent 
even years after completion of therapy. Late onset dysphagia has 
been reported to remain unchanged in 48% of patients’ years 
after completion of therapy (11, 12). It is therefore clear that a 
better understanding of factors that drive late toxicities in this 
population is needed, in order to improve long-term function of 
OTC patients.
Designing radiation plans that limit dose heterogeneity and 
maximum dose is a critical part of the radiation treatment plan-
ning process. RTOG 0920, an active phase III trial of surgery 
and postoperative radiation ± cetuximab mandates a maximum 
dose (or hot spot) outside of the PTV to be limited to ≤110% 
of the prescribed dose. Keeping the maximum dose to ≤110% 
is ideal, as hot spots above 110% put normal tissue at risk for 
significant side effects of radiation. In order to minimize the 
maximum dose, or hot spot, dosimetrists create optimization 
planning target volumes (OPTI-PTV) and create avoidance 
structures for OARs. However, for some difficult cases where the 
initial optimization meets all given parameters but has a hot spot 
greater than 110%, the dosimetrist will convert an isodose line of 
less than 110% (between 106 and 108%) to a control point struc-
ture and reoptimize the plan starting from the last iteration and 
give a constraint of equivalent dose of the structure with a high 
priority. In the majority of cases this will minimize the hot spot 
below 110%. The dosimetrist can create another control point 
structure and repeat the same process or they can manipulate 
the normal tissue optimization settings and reoptimize the plan. 
That can be done alone or combined with the second control 
point structure. In most cases, these steps will drop the hot spot 
to less than 110%.
Prophylactic gastrostomy tube placement has been routinely 
offered to patients with locally advanced head and neck cancer 
prior to initiating definitive chemoradiation therapy at our insti-
tution. During treatment, patients are closely assessed by speech 
pathologists to determine swallowing function. After completion 
of therapy, PEG tube removal is recommended if patients are able 
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to tolerate all nutrition orally for at least 2 weeks and adequately 
maintain weight. In the past, we have reported that 25% of elderly 
patients with oropharyngeal squamous cell carcinoma develop 
PEG tube dependency (13). In this study, 13% of patients devel-
oped PEG tube dependency. This is lower than cases reported in 
existing literature and our previous experience (14, 15). Inclusion 
of only OTC patients in our analysis may be a contributor for this 
result. Furthermore, non-adherence to swallowing exercises has 
been suggested to be related this late toxicity (16), even though 
compliance to swallowing exercises was not assessed, it is possible 
that potential higher adherence in our patient population may 
contribute to lower PEG tube dependency. Prior studies have 
also demonstrated that preoperative weight loss, heavy alcohol 
use, low socioeconomic status, and lack of social support (i.e., the 
absence of a partner) are also risk factors for the development of 
long-term PEG tube dependency (17–22).
Pain following head and neck cancer therapies often leads to 
significant psychological and physical suffering resulting in long-
term narcotic dependency. Radiation-induced mucositis typically 
improves 4–6 weeks after completion of treatment (23); however, 
50% of patients treated with RT with and without chemotherapy 
were unable to discontinue opioid use more than 3 months after 
completion of therapy, and 33% of patients required continued 
opioid use at 6  months (24). Here, we showed that 34% of 
patients continue to use narcotics 6 months after the completion 
of therapy. A large systematic review analysis showed that after 
completion of multimodality therapy, pain was increased in 33% 
of patients compared to the pretreatment baseline and unchanged 
in 36% of patients with locally advanced head and neck cancer 
(25). These previous studies did not clearly delineate subtypes of 
HNCs and reported results as a general group. In this study, we 
demonstrate that OTC patients have similar long-term narcotic 
dependency rates as compared to other subsites. While much of 
the increased pain has been associated with mucositis leading to 
the development of narcotic dependency, neither pain level nor 
previous history of substance abuse were assessed among these 
patients, which has been associated with development of narcotic 
dependency in patients with HNC (24).
In our study, 3.9% of patients developed ORN, within previ-
ous reports in the literature. The incidence of ORN was estimated 
to be 4.74–37.5% historically; however, less than 5% incidence 
has been reported in recent studies, likely attributed to the 
improvement of dental care and radiation techniques (26–31). 
No association between ORN and RT was demonstrated in our 
series, which is likely due to the low number of ORN events 
in this study. Furthermore, in addition to radiation dose, there 
are many other risk factors for developing ORN including 
oral hygiene, dental extractions, nutritional status, alcohol, 
and tobacco use (24, 30, 32, 33). Tobacco and alcohol use may 
directly cause ORN due to its effects on mucosal breakdown, 
but they are also surrogates for poor oral hygiene. Patients with 
poor oral hygiene are reported to have a 3.06 times greater odds 
of developing non-resolving ORN than patients with good oral 
hygiene (34).
There are several limitations of this study. First, the retrospec-
tive nature of this study hinders the ability to collect data on 
other relevant late toxicity endpoints for this patient population, 
including fibrosis and more detailed data regarding swallowing 
function and xerostomia. Additionally, other risk factors for 
developing late toxicities, including tobacco use, were not con-
sistently reported and therefore were not included in this analysis. 
Second, the cohort included in this study included oral tongue 
patients only; therefore, the number of patients was small with 
a median follow-up time of 25.8 months. This small sample size 
is likely underpowered to detect potential significant differences. 
Furthermore, improvements in treatment planning techniques 
during the time period of this study could have also accounted 
for variation in treatment-related toxicity. There is certainly a 
learning curve with IMRT treatment planning; however, in order 
to generate a large cohort of oral tongue patients, the study time 
period is somewhat extensive and thus variability in treatment 
planning over time remains an issue. Larger prospective studies 
are required to overcome such limitations in order to provide 
improved insights into the development of late toxicities.
In conclusion, this study demonstrates that the risk of long-term 
narcotic dependence, ORN, or PEG tube dependence is 38% after 
completion of multimodality treatment for OTC. Furthermore, 
the development of long-term PEG tube dependency in these 
patients was significantly associated with higher RT maximum 
dose. Further evaluation of late toxicities in the randomized set-
ting is needed in order to better understand patient-specific and 
treatment-related risk factors that may increase the likelihood of 
late side effects after treatment. Care should be taken to minimize 
the “hot spot” in radiation planning for patients with OTC treated 
postoperatively in order to reduce the risk of long-term PEG tube 
dependency.
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